Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells

A. Tkachenko, K. Kupcova, O. Havranek

. 2023 ; 25 (1) : . [pub] 20231219

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007872

Grantová podpora
AZV NV18-03-00117 Czech Health Research Council
PRIMUS/17/MED/9, UNCE/MED/016, Cooperatio Charles University in Prague
Programme EXCELES, reg. No. LX22NPO5102 European Union - Next Generation EU
Ukraine Bridge Funding Award European Hematology Association

B-cell receptor (BCR) is a B cell hallmark surface complex regulating multiple cellular processes in normal as well as malignant B cells. Igα (CD79a)/Igβ (CD79b) are essential components of BCR that are indispensable for its functionality, signal initiation, and signal transduction. CD79a/CD79b-mediated BCR signaling is required for the survival of normal as well as malignant B cells via a wide signaling network. Recent studies identified the great complexity of this signaling network and revealed the emerging role of CD79a/CD79b in signal integration. In this review, we have focused on functional features of CD79a/CD79b, summarized signaling consequences of CD79a/CD79b post-translational modifications, and highlighted specifics of CD79a/CD79b interactions within BCR and related signaling cascades. We have reviewed the complex role of CD79a/CD79b in multiple aspects of normal B cell biology and how is the normal BCR signaling affected by lymphoid neoplasms associated CD79A/CD79B mutations. We have also summarized important unresolved questions and highlighted issues that remain to be explored for better understanding of CD79a/CD79b-mediated signal transduction and the eventual identification of additional therapeutically targetable BCR signaling vulnerabilities.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007872
003      
CZ-PrNML
005      
20250120155652.0
007      
ta
008      
240412s2023 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms25010010 $2 doi
035    __
$a (PubMed)38203179
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Tkachenko, Anton $u BIOCEV, First Faculty of Medicine, Charles University, Prumyslova 595, 252 50 Vestec, Czech Republic $1 https://orcid.org/0000000210291636 $7 xx0328071
245    10
$a B-Cell Receptor Signaling and Beyond: The Role of Igα (CD79a)/Igβ (CD79b) in Normal and Malignant B Cells / $c A. Tkachenko, K. Kupcova, O. Havranek
520    9_
$a B-cell receptor (BCR) is a B cell hallmark surface complex regulating multiple cellular processes in normal as well as malignant B cells. Igα (CD79a)/Igβ (CD79b) are essential components of BCR that are indispensable for its functionality, signal initiation, and signal transduction. CD79a/CD79b-mediated BCR signaling is required for the survival of normal as well as malignant B cells via a wide signaling network. Recent studies identified the great complexity of this signaling network and revealed the emerging role of CD79a/CD79b in signal integration. In this review, we have focused on functional features of CD79a/CD79b, summarized signaling consequences of CD79a/CD79b post-translational modifications, and highlighted specifics of CD79a/CD79b interactions within BCR and related signaling cascades. We have reviewed the complex role of CD79a/CD79b in multiple aspects of normal B cell biology and how is the normal BCR signaling affected by lymphoid neoplasms associated CD79A/CD79B mutations. We have also summarized important unresolved questions and highlighted issues that remain to be explored for better understanding of CD79a/CD79b-mediated signal transduction and the eventual identification of additional therapeutically targetable BCR signaling vulnerabilities.
650    12
$a receptory antigenů B-buněk $x genetika $7 D011947
650    12
$a signální transdukce $7 D015398
650    _2
$a buněčná membrána $7 D002462
650    _2
$a kognice $7 D003071
650    _2
$a mutace $7 D009154
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Kupcová, Kristýna $u BIOCEV, First Faculty of Medicine, Charles University, Prumyslova 595, 252 50 Vestec, Czech Republic $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000249139877 $7 xx0328095
700    1_
$a Havranek, Ondrej $u BIOCEV, First Faculty of Medicine, Charles University, Prumyslova 595, 252 50 Vestec, Czech Republic $u First Department of Internal Medicine-Hematology, General University Hospital and First Faculty of Medicine, Charles University, 128 08 Prague, Czech Republic $1 https://orcid.org/0000000158263557 $7 xx0128548
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 25, č. 1 (2023)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38203179 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20250120155650 $b ABA008
999    __
$a ok $b bmc $g 2081716 $s 1217639
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 25 $c 1 $e 20231219 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a AZV NV18-03-00117 $p Czech Health Research Council
GRA    __
$a PRIMUS/17/MED/9, UNCE/MED/016, Cooperatio $p Charles University in Prague
GRA    __
$a Programme EXCELES, reg. No. LX22NPO5102 $p European Union - Next Generation EU
GRA    __
$a Ukraine Bridge Funding Award $p European Hematology Association
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace